Ron Firestein
About
Director, Centre for Cancer Research, Hudson Institute of Medical Research
Hudson Institute of Medical Research
Associate Professor Ron Firestein is the Head of the Cancer Centre at the Hudson Institute of Medical Research and Head of Research for the Hudson Monash Paediatric Precision Medicine Program. A/Prof Firestein is a physician scientist double board certified in Pathology (Anatomic and Molecular Genetics) and his research focuses on identifying new targets and developing therapies for solid tumour malignancies.
A/Prof Firestein earned his BA from the University of Pennsylvania in Biology and his MD/PhD from Stanford University as part of the Medical Scientist Training Program (MSTP). He completed residency in Anatomic Pathology at the Brigham and Women’s Hospital and fellowships in molecular pathology and cancer genetics at Harvard Medical School and the Broad Institute.
Prior to joining the Hudson Institute in August 2015 as head of the Centre for Cancer Research, A/Prof Firestein led a basic research lab at Genentech Inc., where he focused on developing integrative genomic technologies to identify new therapeutic targets in solid tumor malignancies. His scientific work has resulted in peer-reviewed high impact publications (including Nature, Cancer Cell, Cell, and Journal of Clinical Investigation) as well as seven patents.
Hudson Institute of Medical Research
scientific
Projects
Data
Ongoing
Hudson Monash Paediatric Precision Medicine Program
There is a great need to find new targets for pediatric brain cancer therapeutics, requiring comprehensive analysis of tumor types. Access to the unique dataset available through the Pediatric Brain Tumor Atlas and computational support from CBTN will allow researchers to carry out this research.
All Brain Tumor Types
Ron Firestein
Specimen
Ongoing
Functional Dependency Mapping in Paediatric Brain Cancers
The treatment of pediatric high grade gliomas could be improved and enhanced with a deeper understanding of their genetic and molecular characteristics. Using specimens from the Children’s Brain Tumor Network, researchers are exploring new therapeutic opportunities for pHGG.
Ron Firestein